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The Ras GTPase plays an essential role in many
cellular signal transduction events. Activation of the
mitogen activated protein (MAP) kinase is a primary
consequence of Ras activation and plays a key role in
mediating Ras signal transduction. A novel kinase,
KSR, has recently been functionally isolated as a
positive regulator of Ras signaling in Caenorhabditis
elegans vulval induction and Drosophila photoreceptor
differentiation. We have examined the effect of KSR
on growth factor and Ras-induced MAP kinase sig-
naling in mammalian cells. Surprisingly, we observed
that KSR specifically blocks EGF and Ras-induced
phosphorylation and activation of ternary complex
factors (TCF), physiological substrates of MAP kinases,
without affecting the activation of MAP kinase itself.
A kinase-deficient mutant of KSR, KSR-RM, appears
to function as a dominant interfering mutant which
elevates phosphorylation of Elk-1, a member of the
TCF family, and Elk-1-dependent transcription. The
effect of KSR on Elk-1 was significantly decreased by
inhibition of calcineurin, a putative Elk-1 phosphatase.
These observations demonstrate that KSR is capable
of uncoupling the MAP kinase activation from its
target phosphorylation, and thus provide a novel
mechanism for modulating the Ras–MAP kinase sig-
naling pathway. This study provides the first evidence
that signal output of MAP kinase cascades is subject




Activation of the Ras-mitogen activated protein kinase
(MAP kinase, also known as extracellular signal regulated
kinase, ERK) cascade is essential for numerous signal
transduction pathways including tyrosine kinase receptors,
trimeric G-protein-coupled receptors and tyrosine kinase-
associated receptors (reviewed in Marshall, 1995;
Denhardt, 1996; Robinson and Cobb, 1997). The best
understood system is the activation of Ras by receptor
tyrosine kinases (van der Geer et al., 1994; Katz and
McCormick, 1997). Binding of mitogenic growth factors
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to its tyrosine kinase receptors results in the activation of
Ras. Activated Ras has an essential role in the activation
of Raf, which directly phosphorylates and activates MEK,
also known as MAP kinase kinase. The activated MEK,
in turn, phosphorylates ERK on threonine and tyrosine
residues and results in a dramatic activation of ERK. This
MAP kinase cascade has been highly conserved throughout
evolution and is found in all eukaryotes, including yeast,
Caenorhabditis elegans, Drosophila and mammals
(Marshall, 1995). In addition, several MAP kinase related
kinases have been discovered. For example, JNK (c-Jun
N-terminal kinase, also known as SAPK for stress activated
protein kinase) has been found to respond to various stress
conditions and phosphorylates and activates c-jun (Hibi
et al., 1993; Derijard et al., 1994; Kyriakis et al., 1994).
Another well-characterized cascade is the p38 kinase,
which is activated by various cytokines and other stimuli
(Han et al., 1994; Lin et al., 1995). Both JNK and p38
kinases share a high degree of structural similarity as well
as a biochemical mechanism of activation that closely
resembles the Raf–MEK–ERK pathway, although different
MAP kinase cascades are activated by a set of overlapping
and distinct extracellular stimuli.
MAP kinase pathways are involved in numerous
developmental programs in model organisms such as
C.elegans and Drosophila. Genetic studies in C.elegans
and Drosophila have identified a novel protein kinase,
KSR (kinase suppressor of Ras) as having a positive
role in mediating Ras signaling (Kornfeld et al., 1995;
Sundaram and Han, 1995; Therrien et al., 1995). Mamma-
lian homologs of KSR have also been identified. Mutations
of KSR can suppress the phenotype of a constitutively
active mutant of Ras, suggesting that KSR functions
downstream of, or parallel to Ras. Mutations in KSR
combined with a weak loss-of-function allele of Raf result
in a synthetic phenotype, indicating that KSR may function
parallel to Raf. Genetic data have established a role of
KSR in Ras–MAP kinase signaling, however, the exact
function of KSR in the pathway is not clear. The deduced
amino acid sequence indicates that KSR is related to the
Raf family of protein kinases. Recently, investigators have
reported that KSR may indirectly modulate MAP kinase
activation in Xenopus oocytes (Therrien et al., 1996) while
others showed activation of KSR by ceramide (Zhang
et al., 1997).
Identification of ERK substrates has provided critical
information for understanding the signal transduction of
the MAP kinase cascade. Activation of Ras–MAP kinase
is known to be essential for the expression of many growth
factor-inducible genes. One of the best characterized ERK
substrates is Elk-1, which is a member of the TCF (ternary
complex factor) family (Gille et al., 1992, 1995; Janknecht
et al., 1993; Marias et al., 1993; Kortenjann et al., 1994).
Elk-1 belongs to a large family of Ets domain-containing
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transcription factors. Members of the Ets family are
thought to be involved in regulation of cell transformation
and differentiation. Elk-1 contains an N-terminal Ets-like
DNA binding domain and a C-terminal ERK responsive
transactivation domain. Phosphorylation by activated ERK
increases transcriptional activity of Elk-1. This event
appears to be critical for ERK-mediated transcription
stimulation, as mutation of these phosphorylation sites
severely diminishes Elk-1 activity. The C-terminal domain
of Elk-1 contains multiple ERK phosphorylation sites. It
has been shown that phosphorylation of serine 383 of
Elk-1 is critical for the transcriptional activation of Elk-1
(reviewed in Hill and Treisman, 1995). Serine 383 is
conserved in two other members of the TCF family,
SAP1 and SAP2. Similarly, phosphorylation of these
corresponding serine residues is essential for the transcrip-
tion activity of SAP1 and SAP2 (Giovane et al., 1994;
Janknecht and Hunter, 1997). In addition to ERK, both
JNK and p38 have been implicated to have a role in
regulation of the TCF family members in response to
different extracellular signals (Cavigelli et al., 1995;
Janknecht and Hunter, 1997; Whitmarsh et al., 1997).
Most of the studies pertaining to MAP kinase signal
transduction have identified components directly activating
or inactivating the ERK pathway. In fact, a linear pathway
from Ras activation to Elk-1 phosphorylation has been
established. We have examined the function of KSR on
activation and phosphorylation of ERK and Elk-1. Our
data show that KSR has no detectable effect on the activity
of ERK but blocks growth factor and Ras-induced Elk-1
phosphorylation, which is absolutely ERK-dependent.
Similarly, KSR blocks EGF-induced Elk-1 activity. This
effect of KSR on Elk-1 appears to require the integrity of
its kinase domain since a mutant, KSR-RM, does not
inhibit Elk-1. In fact, KSR-RM enhances both Elk-1
phosphorylation and transactivation activity in unstimu-
lated cells. Our results provide a novel function for KSR
in modulating the Ras–MAP kinase signal transduction
by specifically affecting the activation of Elk-1.
Results
KSR expression does not affect MAP kinase
activation in mammalian cells
Previous studies suggest that KSR could act either in
parallel to, or on, the Raf–MEK–ERK kinase cascade.
Studies in Xenopus oocytes have indicated that KSR
may indirectly potentiate ERK activation while other
experiments suggest that KSR may activate Raf (Therrien
et al., 1996; Zhang et al., 1997). We performed experiments
to investigate whether KSR can activate the MAP kinase
cascade in cultured mammalian cells. Hemagglutinin anti-
gen (HA)-tagged ERK1 was co-transfected into COS1
cells. Transfected cells were rendered quiescent by incubat-
ing in low serum medium followed by stimulation with
EGF. Co-expression of KSR did not effect basal or
stimulated ERK1 activity (Figure 1A and B). Similarly,
KSR did not noticeably alter the basal or EGF-stimulated
activity of co-transfected MEK1 as determined by an
immune-complex kinase assay (data not shown). In con-
trast, co-expression of Ras or a constitutively active MEK1
mutant significantly activated ERK1.
Activation of ERK1 by co-transfection with Ras or
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Fig. 1. KSR does not alter the activation of ERK1. (A) Effect of KSR
on ERK1 activity. COS1 cells in 6 cm dishes were transfected with
0.25 μg of HA-ERK1 (pJH-ERK1; Sells and Chernoff, 1995) in the
presence or absence of 1 μg pcDNA3-KSR as indicated. RM denotes
the kinase-deficient mutant of KSR. Cells were left untreated or
treated with EGF (50 ng/ml, 5 min) as indicated. Co-transfection with
either 0.5 μg of RasV12 or MEK1d* (a constitutively active MEK1
mutant) were not treated with EGF. HA-ERK1 was
immunoprecipitated with anti-HA antibody and assayed for kinase
activity using myelin basic protein as a substrate. The same EGF
concentration was used for all the experiments in this report. Results
presented (Figures 1–6) are a representative of at least three
independent experiments. (B) Western blot of immunoprecipitated
HA-ERK1. Lanes are as stated in (A). Anti-ERK antibody was used to
detect the HA-ERK1 precipitated by anti-HA.
constitutively active MEK1 mutant was also not affected
by co-transfection of KSR (Figure 1A and B). Activation
of ERK1 requires phosphorylation of two conserved
threonine and tyrosine residues. Western blots performed
with a phosphorylation state-specific anti-ERK antibody
confirmed the results of the kinase activity assays. KSR
expression had no detectable effect on ERK phosphoryl-
ation (Figure 5A, panel pERK). Identical results were
obtained if PMA was used to stimulate MAP kinase
activity instead of EGF (data not shown). These results
suggest that KSR plays no direct role in either activation
or inactivation of MEK–ERK.
KSR blocks transcriptional activation of Elk-1
Activated MAP kinase is able to phosphorylate numerous
cellular proteins and thus directly regulate their functions.
One ERK target is the TCF, which cooperates with the
serum response factor (SRF) to regulate transcription of
promoters containing the serum response element (SRE)
(Gille et al., 1992, 1995; Janknecht et al., 1993; Marias
et al., 1993; Kortenjann et al., 1994). To test the effect
of KSR on Elk-1 transcription activity, the activity of a
KSR inhibits Elk-1 phosphorylation and activation
Fig. 2. KSR blocks Elk-1-dependent transcription activity. (A) KSR
inhibits EGF-induced Gal4–Elk-1 reporter expression. COS1 cells
were transfected with 0.2 μg of Gal4–LUC and 0.05 μg of Gal4–Elk-1
together with increasing amounts of pcDNA3-HA-KSR. MEKdn
denotes 1.0 μg of the dominant-negative MEK1 plasmid. A pCMV-
lacZ plasmid (0.1 μg) was co-transfected as an internal control for
variations in transfection efficiency. The transfected cells were left
untreated (open bars) or treated (hatched bars) with EGF for 8 h.
Luciferase activity was measured and normalized against the
co-transfected β-galactosidase activity. (B) KSR inhibits Ras and
MEK1-induced Gal4–Elk-1 reporter activity. Gal4–Elk-1 reporter was
co-transfected with RasV12 (0.5 μg) or constitutively active MEK1*
(0.1 μg) together with ERK1 (0.1 μg) into COS1 cells. The presence
of KSR (1.0 μg) is indicated. (C) Effect of KSR on Gal4–Elk-1
reporter activity in NIH-3T3 cells. NIH-3T3 cells were co-transfected
with RasV12 or v-Raf together with Gal4–Elk-1 and Gal4-LUC as
above. 24 h post-transfection, cells were incubated in low serum media
for additional 24 h and luciferase activity was determined as above.
Error bars indicate SD from experiments performed in triplicate.
Shown is a representative example of at least three independent
experiments.
Gal4–Elk-1 reporter (Marias et al., 1993), which contains
the C-terminal ERK responsive domain of Elk-1 fused to
the DNA binding domain of Gal4, was tested. The
transcription activity of Gal4–Elk-1 is dependent on
phosphorylation of the Elk-1 trans-activation domain by
ERK. We observed that KSR co-transfection effectively
blocked both basal and EGF-stimulated expression of the
reporter in a dose dependent manner (Figure 2A). Both
untagged and HA-tagged KSR showed identical inhibition
of the Gal4–Elk-1 reporter (data not shown). A dominant-
negative MEK1 mutant, which has the activation phos-
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phorylation serine residues 218 and 222 replaced by
alanine residues, effectively blocked Gal4–Elk-1 activation
as expected (Figure 2A), indicating that ERK activation
is indeed required for EGF-induced Gal4–Elk-1 activation.
The epistatic relationship between KSR and other com-
ponents in the Ras–MAP kinase pathway was examined
with respect to Gal4–Elk-1 activity by co-transfection
with constitutively active mutants of either Ras, Raf or
MEK. We observed that RasV12-stimulated Gal4–Elk-1
reporter activity was completely inhibited by co-transfec-
tion with KSR in COS1 cells (Figure 2B), supporting
previous reports that KSR functions downstream of Ras
(Kornfeld et al., 1995; Sundaram and Han, 1995; Therrien
et al., 1995). KSR also blocked constitutively active
MEK1-induced Gal4–Elk-1 reporter activation. Transfec-
tion of v-Raf in NIH-3T3 cells resulted in a significant
enhancement of Gal4–Elk-1 reporter activity. Expression
of KSR effectively blocked v-Raf-induced Gal4–Elk-1
activity in NIH-3T3 cells (Figure 2C). Similarly, KSR
inhibited RasV12-induced Gal4–Elk-1 activation in NIH-
3T3 cells (Figure 2C). These observations indicate that
KSR functions at a level distinct from known members
of the MAP kinase cascade and that the inhibition of
Elk-1 transcription is not cell-type specific.
To test whether the inhibition of KSR on Gal4–Elk-1
is specific to Elk-1 rather than a global inhibition of
transcription, we performed similar experiments with the
Gal4–Jun reporter (Coso et al., 1995). It has previously
been demonstrated the activation of the JNK pathway by
RacV12 will activate the Gal4–Jun reporter (Coso et al.,
1995; Minden et al., 1995). KSR affected neither basal
nor Rac1V12-induced Gal4–Jun reporter activity (Figure
3A). It should be emphasized that the Gal4–Jun reporter
and the Gal4–Elk reporter are identical except that the Gal4
DNA-binding domain is fused to a different transactivation
domain of either the C-terminal ERK-responsive domain
of Elk-1 or the N-terminal JNK-responsive domain of c-Jun
(Marias et al., 1993; Lin et al., 1995). These observations
clearly demonstrate that the effect of KSR on Elk-1
is specific.
KSR expression blocks induction of a c-fos
reporter gene
The inhibition of Gal4–Elk-1 by KSR that we observed
might simply be an artifact of an artificial chimera tran-
scription factor. To test the effect of KSR on a physiological
promoter using endogenous transcription factors, we
examined the c-fos reporter for gene expression. The c-fos
promoter contains DNA elements for multiple transcription
factors, including a functional serum responsive element
(SRE) (Hill and Treisman, 1995). SRF together with TCF
is responsible for the transcription activation of the SRE
(Hill and Treisman, 1995). KSR expression effectively
blocked Ras-induced activation of the reporter (Figure
3B) as well as EGF- and PMA-induced c-fos reporter
activity (data not shown). The inability of KSR to block
the basal activity of the c-fos reporter is probably due to
the fact that multiple transcription elements exist in
the c-fos promoter, which may contribute to the basal
expression. In agreement with this is our observation that
KSR expression has no effect on Gal4–Jun activity, which
is a component of the AP-1 transcription factor.
In order to test whether KSR specifically inhibited the
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Fig. 3. Effect of KSR on Gal4–Jun and c-fos reporters. (A) KSR has no effect on Gal4–Jun activity. Cells were transfected with 0.5 μg of Gal4–
LUC, 0.2 μg of Gal4–Jun and 1.0 μg of either pcDNA3, pcDNA3-HA-KSR or a constitutively active mutant of Rac1 (Rac1V12; Minden et al.,
1995) as indicated. Reporter activity was measured the same as experiments with Gal4–Elk-1 shown in Figure 2. (B) KSR blocks the effect of
RasV12 on a c-fos reporter. A luciferase reporter (0.2 μg) controlled by the c-fos promoter (Yamauchi et al., 1993) was co-transfected together with
vector control of RasV12 in the presence (hatched bars) or absence (open bars) of KSR. (C) KSR blocks TNF-α- or sorbitol-induced Elk-1 reporter
activation. CV-1 cells were transfected with Gal4–LUC or Gal4–Elk-1 in the presence (hatched bars) or absence (open bars) of KSR. Cells were
treated with EGF (50 ng/ml), TNF-α (10 ng/ml) or sorbitol (600 mM, see Materials and methods). Error bars indicate SD from experiments
performed in triplicate. Shown is a representative example of at least three independent experiments. (D) Western blot for expression of KSR. The
expression of transfected KSR was detected by anti-HA antibody. The samples are identical to those in panel C. (E) KSR inhibits EGF- and PMA-
induced SAP1a and SAP2 activity. CV-1 cells were transfected with Gal4–Elk-1 (lanes 1–6), Gal4–SAP1a (lanes 7–12) or Gal4–SAP2 (lanes 13–18)
together with Gal4–LUC and KSR as indicated. Open and hatched bars denote co-transfection of vector or KSR, respectively. Serum-starved cells
were stimulated for 8 h with EGF (50 ng/ml) or PMA (100 nM) and luciferase activity was determined and normalized as in Figure 2A. Error bars
indicate SD from experiments performed in duplicate. Shown is a representative example of at least three independent experiments.
ERK-induced Elk-1 activation or if KSR inhibits Elk
activation in general, we examined the effect of KSR on
other pathways that induce Elk-1 activation. TNF-α is
known to activate the JNK pathway which can also result
in Elk-1 phosphorylation and activation (Cavigelli et al.,
1995). KSR blocked TNF-α-stimulated Elk-1 activation
(Figure 3C and D). Similarly, high osmolarity stimulates
p38 activity and results in Elk-1 activation (Cavigelli
et al., 1995; Whitmarsh et al., 1997). KSR also inhibits
sorbitol-induced Elk-1 activation (Figure 3C), suggesting
that the inhibitory activity of KSR is not dependent on
ERK activation, but rather is specific to Elk-1. Therefore,
KSR function is not limited to ERK-induced Elk-1
activation.
Inhibition of SAP1a and SAP2 by KSR
The TCF family of transcription factors consists of Elk-1,
SAP1a and SAP2, all of which appear to be physiological
substrates of MAP kinase. To test the effect of KSR
on the transactivation activity of SAP1a and SAP2 we
constructed Gal4 fusion proteins consisting of the yeast
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Gal4 DNA-binding domain fused to the C-terminal activ-
ation domain of SAP1a and SAP2. When these expression
vectors were introduced into CV-1 cells and subsequently
stimulated with EGF or PMA, we observed a large
increase in normalized luciferase activity (Figure 3E). Co-
expression of KSR effectively blocked basal, EGF- and
PMA-stimulated reporter activity for all members of the
TCF family (Figure 3E). These results demonstrate that
KSR inhibits the activity of all members of the TCF family.
An intact kinase domain of KSR is required for the
inhibition of Elk-1
All protein kinases contain a conserved, essential lysine
residue in subdomain II (Hanks and Quinn, 1991). Interest-
ingly, the murine KSR contains an arginine (Arg589) in
place of this conserved lysine. To determine if the kinase
activity of KSR was required for its ability to block Elk-1
reporter, Arg589 was mutated to either a lysine or a
methionine residue to generate KSR-RK and KSR-RM,
respectively. We tested the effects of KSR-RM and KSR-
RK on Gal4–Elk-1 reporter activity. Co-transfection of
KSR inhibits Elk-1 phosphorylation and activation
Fig. 4. KSR-RM enhances Elk-1 activity. CV-1 cells were transfected
with Gal4–Elk-1 and Gal4–LUC, as above, together with the indicated
KSR mutant. Serum-starved cells were stimulated with EGF for 8 h
prior to harvesting and determination of luciferase activity. Luciferase
activity was normalized for transfection efficiency as above. Error bars
indicate SD from experiments performed in triplicate. A Western blot
of KSR expression is shown as an insert in the figure. Shown is a
representative example of at least three independent experiments.
wild-type KSR or KSR-RK severely inhibited basal and
EGF-induced Gal4–Elk-1 reporter activity (Figure 4). In
contrast, KSR-RM expression greatly enhanced both basal
and EGF-stimulated reporter activity (Figure 4). Similarly,
the KSR-RM mutant did not inhibit EGF-induced Elk-1
phosphorylation (Figure 5A, lane 9 in panel pElk-1). Since
the KSR-RK mutant behaves identically to wild-type KSR
to block Elk-1 phosphorylation and activity, and KSR-
RM elevates Elk-1 activity, we conclude that the arginine
to lysine substitution is still functional, but substitution to
a methionine results in a loss of function, almost certainly
due to loss of kinase activity. It is interesting to point out
that both Drosophila and C.elegans KSR contains a lysine
at this position. Our results suggest that the integrity of
the kinase domain is essential for KSR’s ability to block
Elk-1 phosphorylation.
KSR blocks Elk-1 phosphorylation without
affecting ERK phosphorylation
Phosphorylation of Ser383 has been shown to be critical
for the transcription activity of Elk-1 (Gille et al., 1992,
1995; Janknecht et al., 1993; Marias et al., 1993;
Kortenjann et al., 1994). KSR could inhibit Elk-1 activ-
ation by either directly blocking Elk-1 phosphorylation or
indirectly repressing Elk-1 activity. To examine the effect
of KSR on Elk-1 phosphorylation directly, an EGF-
stimulated time course of Elk-1 phosphorylation was
performed using a phosphorylation state-specific Elk-1
antibody, which recognizes only the Ser383 phosphoryl-
ated form of Elk-1. Data in Figure 5A show that Elk-1
phosphorylation was acutely stimulated by EGF with
maximum phosphorylation occurring at 5 min. Co-trans-
fection of KSR completely blocked EGF-stimulated Elk-1
phosphorylation (Figure 5B, panel pElk-1). Western blots
with anti-Elk-1 showed that similar amounts of Elk-1
were expressed in all samples (Figure 5B, panel Elk-1).
The kinase-deficient KSR-RM mutant was unable to block
Elk-1 phosphorylation (Figure 5B, lane 9). In parallel, the
same cell lysates were probed with antibody specifically
recognizing phosphorylated ERK. KSR did not affect
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EGF-stimulated HA-ERK1 phosphorylation (Figure 5B,
panel pERK) which was co-transfected with Elk-1 and
KSR. The inhibition of Elk-1 phosphorylation by KSR was
supported by in vivo 32P-labeling and immunoprecipitating
HA-Elk-1 from cells expressing KSR or vector alone. We
observed a significant decrease in 32P-incorporation in
Elk-1 in cells co-expressing KSR, although immuno-
blotting revealed identical amounts of Elk-1 in each
immune-complex (Figure 5C).
Co-expression of RasV12 or an active MEK1 mutant
also resulted in elevated Elk-1 phosphorylation (Figure
5C). Therefore, we next examined the effect of KSR
on Ras and MEK-induced Elk-1 phosphorylation. KSR
completely inhibited active Ras or MEK1-induced Elk-1
phosphorylation (Figure 5C). Dominant-negative MEK1
expression blocked EGF-induced Elk-1 phosphorylation
(Figure 5C). Similarly, the MEK inhibitor PD98059 also
inhibited EGF-stimulated Elk-1 phosphorylation (data not
shown), suggesting that MEK–ERK kinases are required
for EGF-induced phosphorylation of Elk-1.
It is worth noting that expression kinase-deficient KSR,
KSR-RM, did not inhibit Elk-1 phosphorylation (Figure
5A, lane 9, and 5D). In fact, co-transfection with KSR-
RM resulted in an elevation of Elk-1 phosphorylation,
suggesting that KSR-RM functions as a dominant interfer-
ing mutant. The effect of KSR-RM was not due to
activation of ERK because KSR-RM did not increase
either the basal or the stimulated ERK activity (Figure 1),
and also did not increase ERK phosphorylation (Figure
5A, lane 9 in panel pERK). The observation that KSR-RM
expression leads to an increase of Elk-1 phosphorylation is
completely consistent with the ability of wild-type KSR
to block Elk-1 phosphorylation. We examined the relation-
ship between KSR and Ras further using the KSR-RM
mutant. Expression of the RasN17 dominant-negative
mutant (deVries-Smits et al., 1992; Wood et al., 1992)
blocked EGF-induced Elk-1 phosphorylation (Figure 5D).
Co-transfection with KSR-RM partially reversed the
inhibitory effect of RasN17 (Figure 5D), supporting the
hypothesis that KSR-RM functions downstream of Ras.
These results lend further support to our above observ-
ations that a consequence of KSR expression is loss of
Elk-1 activity via a dramatic decrease in Elk-1 phosphoryl-
ation.
KSR inhibits phosphorylation of cytoplasmic
localized lacZ–ElkC
Based on current models of MAP kinase signaling, we
reasoned that there are three known mechanisms that
would explain our novel findings concerning KSR: (i) KSR
expression may lead to a modification of ERK which
renders it unable to phosphorylate Elk-1; (ii) KSR expres-
sion may lead to a modification of Elk-1 that renders it
unsuitable as an ERK substrate and (iii) KSR may affect
the localization of ERK and/or Elk-1.
We first tested whether KSR co-transfection alters
the ability of ERK to phosphorylate Elk-1. ERK1 was
immunoprecipitated from KSR-expressing cells and used
to phosphorylate recombinant glutathione S-transferase
(GST)–Elk-1. MBP was included as an internal control.
Our results showed that ERK1 in KSR co-transfected cells
was fully activated by EGF, and that the activated ERK1
can effectively phosphorylate GST–Elk-1 in vitro (Figure
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Fig. 5. KSR selectively blocks Elk-1 but not ERK phosphorylation. (A) The kinase activity of KSR is required to block Elk-1 phosphorylation.
COS1 cells were transfected with 0.5 μg of pcDNA3-Elk-1, 0.5 μg HA-ERK1 and 1.0 μg of either pcDNA3 (lanes 1, 3, 5 and 7), pcDNA3-HA-
KSR (lanes 2, 4, 6 and 8) or KSR-RM (lane 9). Cells were treated with EGF for the indicated times. Cell lysates were subjected to immunoblot
analysis with anti-pElk-1, anti-Elk-1, anti-pERK, anti-ERK or anti-HA (for HA-KSR) as indicated on the right side of each panel. Anti-Elk-1 and
anti-pElk-1 antibodies specifically recognize the unphosphorylated and phosphorylated Elk-1, respectively. Anti-pERK antibody only recognizes the
phosphorylated ERK while anti-ERK antibody recognizes both the phosphorylated and unphosphorylated ERK. The three bands detected by the anti-
ERK antibody are due to endogenous ERK1 and ERK2 (the lower two bands) and the transfected HA-ERK1 (upper band). (B) KSR blocks Elk-1
phosphorylation. COS1 cells were transfected with HA-Elk-1 with or without KSR, labeled with [32P]-PO4 (0.5 mCi/ml), for 4 h and stimulated with
EGF for 5 min. HA-Elk-1 was immunoprecipitated using the anti-HA antibody. Immunoprecipitated HA-Elk-1 was subjected to autoradiography
(upper panel) or immunoblot with anti-Elk-1 (lower panel). (C) KSR blocks Ras and MEK1 induced Elk-1 phosphorylation. COS1 cells were
transfected with 0.5 μg pcDNA3-Elk-1 together with 1.0 μg of pcDNA3-HA-KSR, RasV12, MEK1* plus ERK1, or MEKdn as indicated. Cell
lysates were probed with either anti-pElk-1 (upper panel) or anti-Elk-1 (lower panel). (D) KSR-RM functions as a dominant interfering mutant and
enhances Elk-1 phosphorylation. Elk-1 was co-transfected with 1.0 μg of either vector (lanes 1 and 2), pcDNA3-HA-KSR (lanes 3 and 4), KSR-RM
(lanes 5 and 6), RasN17 (lanes 9 and 10) or KSR-RM plus RasN17 (lanes 7 and 8). After serum starvation, transfected cells were left untreated or
treated with EGF (5 min). Immunoblots were performed with either anti-pElk-1 (upper panel) or anti-Elk-1 (lower panel).
6A) as determined by both 32P-incorporation and anti-
phospho-Elk-1-specific antibody. The ratio of phosphoryl-
ation of Elk-1 over MBP was not decreased by co-
transfection with KSR. These data exclude the possibility
that KSR alters the substrate specificity of ERK1.
To test whether KSR decreased the efficacy of Elk-1 to
serve as an ERK substrate, an in vitro phosphorylation
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assay of Elk-1 immunoprecipitated from KSR expressing
cells was performed. HA-Elk-1 was co-transfected with
KSR or the kinase-deficient RM mutant. HA-tagged Elk-1
was immunoprecipitated from serum-starved cells and
subjected to in vitro phosphorylation by recombinant
active ERK1. Immunoprecipitated HA-Elk-1 was readily
phosphorylated by recombinant ERK1 in vitro regardless
KSR inhibits Elk-1 phosphorylation and activation
Fig. 6. KSR blocks cytoplasmic localized lacZ–ElkC phosphorylation. (A) KSR does not affect the ability of ERK to phosphorylate Elk-1 in vitro.
HA-ERK1 (0.5 μg) was co-transfected with 1 μg of vector or KSR. The transfected cells were serum-starved and stimulated with EGF for 5 min as
indicated. HA-ERK1 was immunoprecipitated and used to phosphorylate 2 μg of recombinant GST–Elk-1 with cold ATP. Phosphorylation of
GST–Elk-1 was detected by the anti-pElk-1 antibody (upper panel). The immunoprecipitated HA-ERK1 was also used to phosphorylate GST–Elk-1
(2 μg) together with myelin basic protein (MBP, 20 μg) in the presence of [32P]γ-ATP. Phosphorylation of GST–Elk-1 and MBP was detected by
autoradiography (lower panel). (B) KSR does not affect the ability of Elk-1 to serve as an ERK substrate. HA-Elk-1 (0.5 μg) was co-transfected with
1μg KSR or KSR-RM. HA-Elk-1 was immunoprecipitated and subjected to in vitro phosphorylation by buffer control (lanes 1–4) or 10 ng ERK1
(lanes 5–8). The phosphorylation of HA-Elk-1 was detected by anti-pElk. The higher level of pElk-1 in lanes 7 and 8 was due to a comparably
higher level of Elk-1 in the immunoprecipitation (data not shown). (C) lacZ–ElkC fusion is cytoplasmic. pcDNA3-lacZ–ElkC (0.5 μg) was
co-transfected with pcDNA3-Elk-1 and KSR into COS1 cells. Cells were fractionated into cytoplasmic (C) and nuclear (N) fractions and probed with
anti-Elk-1 antibody. Lanes 1 and 3 are transfected with empty vector while lanes 2 and 4 are transfected with pcDNA3-lacZ–ElkC together with
pcDNA3-Elk-1. lacZ–ElkC is cytoplasmic (lane 2) while Elk-1 is nuclear (lane 4). (D) KSR blocks the phosphorylation of cytoplasmic lacZ–ElkC.
pcDNA3-lacZ–ElkC transfected COS1 cells were stimulated with EGF for 5 min as indicated. Western blot was performed with anti-pElk-1 (top
panel, detection of phosphorylation) or anti-Elk-1 (bottom panel, detection of expression). EGF induced a rapid lacZ–ElkC phosphorylation (lane 2)
which was inhibited by KSR (lane 4).
of whether KSR was co-expressed (Figure 6B). Thus,
KSR expression does not affect the ability of Elk-1 to be
phosphorylated by recombinant ERK1, nor does it block
the recognition of the anti-pElk-1 epitope.
Next we tested the third hypothesis: whether KSR alters
the localization of ERK and/or Elk-1. Immunofluorescence
and subcellular fractionation of transfected HA-ERK1 or
HA-Elk-1 in KSR-expressing cells indicated that the
subcellular localization of neither HA-ERK1 nor HA-
Elk-1 was altered (data not shown). We reasoned that if
KSR affects nuclear translocation of ERK, the inhibitory
effect of KSR on Elk-1 phosphorylation should be confined
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to the cell nucleus. To test this possibility, the C-terminal
ERK-responsive domain of Elk-1 was fused to lacZ in a
mammalian expression vector. When COS1 cells were co-
transfected with lacZ–ElkC and wild-type Elk-1, lacZ–
ElkC fusion was localized to the cytoplasm (Figure 6C).
In contrast, wild-type Elk-1 was nuclear as determined
by cell fractionation and immunoblotting (Figure 6C).
Phosphorylation of Elk-1 serine 383 in lacZ–ElkC was
acutely stimulated by EGF identical to the wild-type
Elk-1 (Figure 6D), suggesting that the lacZ–ElkC is
phosphorylated by ERK in a stimulation-dependent
manner. Co-expression of KSR effectively inhibited the
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Fig. 7. Cyclosporin A blocks the effect of KSR. (A) Cyclosporin A blocks the inhibitory effect of KSR. COS1 cells were transfected with pcDNA3-
Elk-1 with or without pcDNA3-HA-KSR (1.0 μg) as indicated. Cells were starved with 0.1% serum for 24 h and stimulated with EGF for the
indicated times. Cyclosporin A (5 μM) was added 30 min prior to the addition of EGF (even numbered lanes). Samples were blotted with the
indicated antibodies. Transfected KSR was detected with anti-HA antibody. (B) Cyclosporin A reverses the inhibitory effect of KSR on Elk-1
phosphorylation. pcDNA3-Elk-1 (0.5 μg) was co-transfected with the indicated amounts of pcDNA3-HA-KSR. After serum starvation, COS1 cells
were left untreated (lanes 1–8) or treated (lanes 9–16) with CsA (5 μM) for 30 min. EGF stimulation was 10 min. Immunoblots were performed
with either anti-pElk-1 (top panel) or anti-Elk-1 (bottom panel). (C) Okadaic acid has no detectable effect on KSR function. COS1 cells were
transfected with pcDNA3-Elk-1 together with KSR as indicated. The cells were starved as described in Figure 6A and pre-incubated with 1 μM
Okadaic acid for 30 min (lanes 3, 4, 7 and 8), followed by stimulation with EGF for 10 min. Cell lysates were probed with either anti-pElk-1
(top panel) or anti-Elk-1 (bottom panel).
phosphorylation of cytosolic lacZ–ElkC. These results
suggest that the inhibitory effect of KSR is not confined
to the nucleus, inconsistent with the possibility that KSR
blocks the nuclear translocation of ERK.
Cyclosporin A blocks the effect of KSR
We examined the effects of phosphatase inhibitors on the
ability of KSR to inhibit Elk-1 serine 383 phosphorylation.
Okadaic acid, an inhibitor of phosphoprotein phosphatases
1 and 2A (PP1 and PP2A), was used in conjunction with
cyclosporin A (CsA), an inhibitor specific to calcineurin,
also known as PP2B, in order to begin to understand the
mechanism by which KSR functions. COS1 cells were
transfected with Elk-1 and KSR and stimulated with EGF
in the presence or absence of CsA. Addition of CsA
significantly reduced the inhibitory effect of KSR on Elk-1
phosphorylation (Figure 7A), particularly when lower
amounts of KSR expression vector were used (Figure 7B).
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Identical experiments using okadaic acid showed no effect
on Elk-1 phosphorylation (Figure 7C). Importantly, the
effect of CsA on Elk-1 phosphorylation was not due to
ERK activation, as ERK phosphorylation is not affected
by either KSR expression or CsA pre-treatment (Figure
7A). This observation suggests a possible role for cal-
cineurin in mediating Elk-1 inactivation by KSR.
Discussion
KSR as a novel regulator of MAP kinase signaling
pathways
The Ras–MAP kinase pathway is one of the most widely
utilized signaling cascades in eukaryotic cells. Its function
has been implicated in many diverse signal transduction
events ranging from cell growth, differentiation and sur-
vival to oncogenic transformation (Robinson and Cobb,
1997). Previously, components identified in this pathway
KSR inhibits Elk-1 phosphorylation and activation
have been shown to modulate activities of other enzymes
in the pathway directly. Phosphorylation of cellular targets
by ERK obviously plays a critical role for signaling in
this pathway. Phosphorylation and activation of the TCF
family transcription factors by MAP kinases have been
shown to mediate transcriptional activation of cellular
genes that are targets of the Ras–MAP kinase pathway.
Here we demonstrate that a hitherto undescribed mechan-
ism exists by which KSR is able to modulate the phos-
phorylation status of Elk-1 without directly altering the
activity of ERK1. The observation that Elk-1 is not
phosphorylated in the presence of KSR even though ERK
is fully phosphorylated and activated suggests that KSR
can uncouple Elk-1 phosphorylation from ERK activation.
Phosphorylation of Elk-1 was determined by anti-phospho-
Elk-1-specific antibody, 32P-labeling and functional ana-
lysis of Elk-1-dependent transcription. Similarly, ERK
activation was determined by both phosphorylation and
kinase activity. The effect of KSR is specific to Elk-1
because KSR does not block RacV12-induced Gal4–Jun
activation. Recently it was reported that KSR is activated
by ceramide and can directly phosphorylate and activate
Raf (Zhang et al., 1997). We were unable to detect Raf-1
activiation by KSR even though similar experimental
conditions were used. We have no explanation for these
discrepancies.
The observations described in this report are likely to
be physiologically relevant, as opposed to being simply
due to an artifact of transient transfection/overexpression,
for the following reasons. First, KSR can block the
expression of the c-fos promoter induced by both onco-
genic Ras and growth factors, which uses endogenous
TCF transcription factors. Secondly, the KSR-RM mutant
does not inhibit Elk-1 phosphorylation, rather it serves to
enhance the phosphorylation of Elk-1. These results sug-
gest that KSR-RM functions as a dominant interfering
mutant and more importantly, are completely consistent
with the observations that a function of wild-type KSR is
to block the activation of Elk-1. Thirdly, the effect of
KSR is specific to the TCF family. Fourthly, KSR also
inhibits TNFα- and sorbitol-induced Elk-1 activation.
Finally, the inhibitory effect of KSR was observed in
several cell lines, including COS1, CV1 and NIH-3T3.
Our studies established that KSR acts as a negative
regulator of Elk-1 phosphorylation in response to growth
factor and Ras signaling.
Our data support the model that KSR functions down-
stream of, or parallel to, the Ras–MAP kinase pathway
and uncouples Elk-1 phosphorylation from ERK activation
(Figure 8). This can be achieved by either preventing
Elk-1 phosphorylation or promoting dephosphorylation.
Our results are consistent with the latter possibility. KSR
affected neither the activation of ERK1 nor the ability of
ERK1 to phosphorylate Elk-1. The subcellular localization
of ERK1 is apparently also not affected by KSR. In
addition, KSR does not decrease the efficacy of Elk-1 to
be phosphorylated by recombinant ERK. Our results
presented here argue against the model that KSR directly
inhibits Elk-1 phosphorylation. However, our data are
consistent with the hypothesis that KSR may promote the
accumulation of dephosphorylated Elk-1 via the action of
a phosphatase rather than inhibiting the activities of
Elk-1 kinases directly. We have recently observed that
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Fig. 8. A proposed model of KSR in regulation of Elk-1. (→) and
(—|) denote positive and negative actions, respectively. Dashed lines
indicate possible indirect effects. KSR inhibition of Elk-1
phosphorylation could be mediated by PP2B (phosphoprotein
phosphatase 2B, also known as calcineurin) dependent or independent
pathways.
calcineurin is the major Elk-1 phosphatase (Sugimoto
et al., 1997). Reversal of the inhibitory effects of KSR
on Elk-1 by inhibition of calcineurin supports the proposed
model and suggests a role for calcineurin in both KSR
and Elk-1 function (Figure 8). The fact that KSR blocked
the ability of different pathways (JNK and p38) to induce
Elk-1 phosphorylation is also consistent with the notion
that KSR promotes Elk-1 dephosphorylation. We propose
that both inactivation of KSR and activation of ERK are
required to achieve maximum activation/phosphorylation
of Elk-1 during receptor tyrosine kinase and Ras signaling
which induce the expression of c-fos. This report provides
the first example showing that TCF activity can be
regulated independently of MAP kinase activity in vivo.
KSR and differential signal output of the MAP
kinase pathway
Genetic studies demonstrate that KSR plays a positive
role in both Ras-induced vulval development of C.elegans
and photoreceptor development of Drosophila (Kornfeld
et al., 1995; Sundaram and Han, 1995; Therrien et al.,
1995). Mutations of KSR suppress the phenotype of a
constitutively active mutant of Ras in both processes. We
report here that KSR has a negative role in growth factor
and Ras-induced Elk-1 activation in mammalian cells.
Interestingly, Elk-1 belongs to the Ets family of transcrip-
tion factors which have been implicated in cell proliferation
(reviewed in Macleod et al., 1992). Elk-1 may play a role
in Ras-induced cell proliferation rather than differentiation.
Lin-1 (Beitel et al., 1995) and Yan (Rebay and Rubin,
1995) are Ets-containing proteins involved in C.elegans
vulval induction and Drosophila photoreceptor differenti-
ation, respectively. Both Lin-1 and Yan are negative
regulators in Ras-mediated differentiation. Therefore,
inhibition of Ets-containing proteins might serve to
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promote cell differentiation. Our data provide a possible
biochemical mechanism for KSR function in Ras–MAP
kinase signal transduction.
It is well established and perplexing that Ras can
promote both cell proliferation and differentiation in
different cell types in response to various extracellular
signals. KSR could play a critical role in suppressing the
proliferative effect of Ras, thereby promoting Ras-induced
differentiation. MAP kinases are activated by a myriad
of extra-cellular stimuli. However, the mechanism for
generating different physiological responses by activation
of a common set of signaling molecules is far from
understood. The function of KSR may be to specifically
affect a subset of MAP kinase substrates without affecting
the phosphorylation of others, thus producing different
cellular responses from a common MAP kinase cascade.
Materials and methods
Cell culture and transfection
COS1, CV-1 and NIH-3T3 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS).
Transfection of COS1, CV-1 and NIH-3T3 cells was done by DEAE-
Dextran (Braiser, 1994) and LipofectAMINE (Gibco-BRL) methods,
respectively. 24 h after transfection, cells were starved for an additional
24 h by incubating with DMEM containing 0.1% FBS prior to stimulation.
Plasmids
All DNA manipulations were performed essentially as described
(Sambrook et al., 1989). To construct epitope-tagged expression plasmids,
we first inserted a DNA fragment encoding a start methionine followed
by three tandem repeats of the hemagglutinin antigen (HA) epitope
(YPYDVPDYA) between the HindIII and NotI sites of pcDNA3
(Invitrogen) to produce the pcDNA3-HA vector. To express HA-epitope
tagged KSR (HA-KSR), the entire coding region of KSR was amplified
by the polymerase chain reaction (PCR) using murine KSR cDNA as a
template (a generous gift of Dr Gerald Rubin). The PCR product was
subcloned into pcDNA3-HA at the unique XbaI–EcoRI sites. KSR was
also subcloned into pcDNA3 without an epitope tag. The XbaI–EcoRI
fragment of KSR coding sequence was also subcloned into pALTER-1
(Promega). Point mutations of KSR were made using the Altered Sites
II in vitro mutagenesis system (Promega). Mutations were confirmed by
DNA sequencing. Mutant KSRs was subcloned into pcDNA3-HA similar
to the wild-type KSR.
To express HA-tagged MEK1 (HA-MEK1), the BamHI fragment of
pGEX-2T-MEK1 (Zheng et al., 1993) was subcloned into pcDNA3-HA
at the BamHI site. The HA-MEK1 plasmid will express MEK1 with
two HA repeats at its N-terminus. To construct an Elk-1 expression
vector, the human Elk-1 cDNA was subcloned into pcDNA3 or pcDNA3-
HA. A constitutively active human MEK1d* was made by deletion of
amino acid residues 32–51 and replacement of Ser218 and 222 by
glutamic acid residues (Mansour et al., 1994). The MEK1* contains the
Ser218 and 222 to glutamic acid only. The dominant-negative form of
MEK1dn was made by changing the Ser218 and 222 to alanines. These
MEK1 mutants were subcloned into the pCMV5 vector (Andersson
et al., 1989). To construct a lacZ–ElkC expression vector, a cDNA
fragment which corresponds to the C-terminus of Elk-1 (amino acids
residues 305–425) was subcloned into the lacZ expression vector
pcDNA3.1(–)/Myc-His/lacZ (Invitrogen).
The activation domains of SAP1a (amino acid residues 323–430) and
SAP2 (amino acid residues 299–407), containing all conserved MAP
kinase phosphorylation sites, were amplified by RT–PCR from human
placenta mRNA and subcloned into a mammalian expression vector in-
frame with a Gal4 DNA binding domain.
Kinase assays
COS1 cells were transfected with HA-c-Raf, HA-ERK1 or HA-MEK1
in the presence or absence of KSR. The transfected cells were serum
starved for 24 h followed by stimulation with 10% FBS or EGF
(50 ng/ml). Transfected cells were lysed in buffer (10 mM Tris–Cl
pH 7.5, 2 mM EDTA, 150 mM NaCl, 1% NP-40, 50 mM NaF, 1 mM
sodium vanadate, 1 mM PMSF and 10 μg/ml aprotinin). HA tagged
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kinases were incubated with 1 μg of 12CA5 antibody (anti-HA) for 2 h
at 4°C followed by addition of protein A agarose (Pierce) for 1 h.
Immunoprecipitated kinases were washed three times with lysis buffer
followed by one wash with 25 mM HEPES pH 7.5, 1 mM DTT and
0.5 mM EDTA. Kinase activities for Raf, MEK and ERK were measured
as described previously (Zheng et al., 1994). GST–MEK1 and GST–
ERK1 were expressed in Escherichia coli and purified as described
previously (Zheng and Guan, 1993). GST–Elk-1 (containing the
C-terminal amino acid residues 305–425) was expressed in E.coli and
purified by glutathione affinity chromatography.
Reporter analysis
Gal4–Elk-1, which contains the C-terminal transactivation domain fused
to the Gal4 DNA binding domain, was co-transfected with Gal4–LUC,
which has the luciferase expression under the control of four tandem
repeats of the Gal4 DNA binding sequence. A pCMV-lacZ plasmid was
co-transfected as an internal control for transfection efficiency and
sample handling. 24 h after transfection, cells were starved in 0.1% FBS
for 24 h followed by stimulation with EGF (50 ng/ml) or TNF-α
(10 ng/ml) for 6–8 h. Cells were lysed in lysis buffer (Braiser, 1994).
Luciferase activity were measured as described (Braiser, 1994). Co-
transfected β-galactosidase activity was also determined and used to
normalize the luciferase activity. When co-transfections were performed
with Ras or MEK1, the transfected cells were also starved in 0.1% FBS
medium for 24 h. However, cells were directly harvested and assayed
for luciferase and β-galactosidase activities without EGF or serum
stimulation. For sorbitol stimulation, transfected cells were starved in
0.1% FBS medium for 24 h and cells were incubated with 600 mM
sorbitol for 1 h. The stimulated cells were cultured in 0.1% FBS medium
without sorbitol for an additional 7 h before harvesting and assaying for
reporter activity.
Cell fractionation
To separate the nuclear and cytoplasmic fractions, transfected COS1
cells (100 mm plate) were washed twice with phosphate buffered
saline and scraped into 1 ml of hypotonic lysis buffer (10 mM
β-glycerolphosphate, 2 mM MgCl2, 10 mM KCl, 1 mM EDTA, 1 mM
EGTA, 1 mM sodium vanadate, 40 μg/ml PMSF, 10 μg/ml leupeptin,
10 μg/ml pepstatin). Cell fractionation was performed as described
previously (Chen et al., 1992; Zheng and Guan, 1994). Both the nuclear
and cytoplasmic fractions were resuspended in equal volume (1 ml) of
the lysis buffer and subjected to SDS–PAGE and immunoblot analysis.
Immunoblot analysis
COS1 cells were directly lysed in SDS sample buffer, subjected to SDS–
PAGE and transferred to a PVDF membrane (Millipore). Typically, a
35 mm plate was lysed in 150 μl SDS sample buffer. After electrophoresis
and transfer, the membranes were probed as indicated in the figure
legends with various antibodies. Immunoreactive bands were detected
by the ECL detection kit (Amersham). Anti-ERK1 antiserum was
prepared against recombinant proteins (Zheng and Guan, 1994). Anti-
HA antibody was prepared using the 12CA5 hybridoma cell line.
Anti-Elk-1 and pElk-1 were purchased from New England Biolabs. Anti-
pERK antibody was purchased from Promega.
Treatment with phosphatase inhibitors, in vivo labeling
To determine the effect of phosphatase inhibitors on KSR function, Elk-1
transfected cells were treated with 1 μM of okadaic acid (Calbiochem) or
5 μM of cyclosporin A (Sigma). After 30 min treatment with phosphatase
inhibitors, cells were stimulated with EGF for the indicated times. Cells
were harvested and subjected to immunoblots with various antibodies
as described above.
For in vivo labeling, COS1 cells were transfected with HA-Elk-1 with
or without KSR. 24 h after transfection, cells were starved in 0.1% FBS
medium for 24 h. Cells were incubated further in phosphate free medium
with 0.1% dialyzed serum (Gibco-BRL) in the presence of 0.5 mCi/ml
32P for 4 h. After EGF stimulation for 5 min, cells were harvested. The
labeled HA-Elk-1 was immunoprecipitated from cell lysates by anti-
HA antibody (as described in the kinase assays) and subjected to
autoradiography or Western blot with anti-Elk-1 antibody.
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